387 related articles for article (PubMed ID: 31228649)
1. Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions.
Leitch HA; Gattermann N
Crit Rev Oncol Hematol; 2019 Sep; 141():54-72. PubMed ID: 31228649
[TBL] [Abstract][Full Text] [Related]
2. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?
Leitch HA; Vickars LM
Hematology Am Soc Hematol Educ Program; 2009; ():664-72. PubMed ID: 20008252
[TBL] [Abstract][Full Text] [Related]
3. Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.
Leitch HA
Drugs; 2011 Jan; 71(2):155-77. PubMed ID: 21275444
[TBL] [Abstract][Full Text] [Related]
4. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
Leitch HA; Parmar A; Wells RA; Chodirker L; Zhu N; Nevill TJ; Yee KWL; Leber B; Keating MM; Sabloff M; St Hilaire E; Kumar R; Delage R; Geddes M; Storring JM; Kew A; Shamy A; Elemary M; Lenis M; Mamedov A; Ivo J; Francis J; Zhang L; Buckstein R
Br J Haematol; 2017 Oct; 179(1):83-97. PubMed ID: 28677895
[TBL] [Abstract][Full Text] [Related]
5. Iron overload in lower international prognostic scoring system risk patients with myelodysplastic syndrome receiving red blood cell transfusions: Relation to infections and possible benefit of iron chelation therapy.
Wong CAC; Wong SAY; Leitch HA
Leuk Res; 2018 Apr; 67():75-81. PubMed ID: 29477023
[TBL] [Abstract][Full Text] [Related]
6. Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy.
Shammo JM; Komrokji RS
Expert Rev Hematol; 2018 Jul; 11(7):577-586. PubMed ID: 29902097
[TBL] [Abstract][Full Text] [Related]
7. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.
Shenoy N; Vallumsetla N; Rachmilewitz E; Verma A; Ginzburg Y
Blood; 2014 Aug; 124(6):873-81. PubMed ID: 24923296
[TBL] [Abstract][Full Text] [Related]
8. Controversies surrounding iron chelation therapy for MDS.
Leitch HA
Blood Rev; 2011 Jan; 25(1):17-31. PubMed ID: 21030120
[TBL] [Abstract][Full Text] [Related]
9. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.
Kikuchi S; Kobune M; Iyama S; Sato T; Murase K; Kawano Y; Takada K; Ono K; Kaneko Y; Miyanishi K; Sato Y; Hayashi T; Takimoto R; Kato J
Free Radic Biol Med; 2012 Aug; 53(4):643-8. PubMed ID: 22705364
[TBL] [Abstract][Full Text] [Related]
10. Unraveling the mechanisms behind iron overload and ineffective hematopoiesis in myelodysplastic syndromes.
Angelucci E; Cianciulli P; Finelli C; Mecucci C; Voso MT; Tura S
Leuk Res; 2017 Nov; 62():108-115. PubMed ID: 29054020
[TBL] [Abstract][Full Text] [Related]
11. Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform.
Valent P; Krieger O; Stauder R; Wimazal F; Nösslinger T; Sperr WR; Sill H; Bettelheim P; Pfeilstöcker M
Eur J Clin Invest; 2008 Mar; 38(3):143-9. PubMed ID: 18218040
[TBL] [Abstract][Full Text] [Related]
12. Myelodysplastic syndromes and the role of iron overload.
Harvey RD
Am J Health Syst Pharm; 2010 Apr; 67(7 Suppl 2):S3-9. PubMed ID: 20332503
[TBL] [Abstract][Full Text] [Related]
13. [The role of iron metabolism in myelodysplastic syndromes].
Finelli C; Clissa C; Stanzani M
Recenti Prog Med; 2014 Mar; 105(3):123-6. PubMed ID: 24675455
[TBL] [Abstract][Full Text] [Related]
14. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
Delforge M; Selleslag D; Triffet A; Mineur P; Bries G; Graux C; Trullemans F; MacDonald K; Abraham I; Pluymers W; Ravoet C
Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
[TBL] [Abstract][Full Text] [Related]
15. To chelate or not to chelate in MDS: That is the question!
Zeidan AM; Griffiths EA
Blood Rev; 2018 Sep; 32(5):368-377. PubMed ID: 29602612
[TBL] [Abstract][Full Text] [Related]
16. Do Recent Randomized Trial Results Influence which Patients with Myelodysplastic Syndromes Receive Iron Chelation?
Gattermann N
Hematol Oncol Clin North Am; 2020 Apr; 34(2):465-473. PubMed ID: 32089223
[TBL] [Abstract][Full Text] [Related]
17. Iron overload in myelodysplastic syndromes: diagnosis and management.
List AF
Cancer Control; 2010 Jan; 17 Suppl():2-8. PubMed ID: 20125080
[TBL] [Abstract][Full Text] [Related]
18. Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?
Wong SA; Leitch HA
Leuk Res; 2018 Jan; 64():24-29. PubMed ID: 29149650
[TBL] [Abstract][Full Text] [Related]
19. Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes.
Malcovati L
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S305-11. PubMed ID: 19778858
[TBL] [Abstract][Full Text] [Related]
20. Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome.
Zeidan AM; Pullarkat VA; Komrokji RS
Crit Rev Oncol Hematol; 2017 Sep; 117():57-66. PubMed ID: 28807236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
